Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 33.11% is 20% above its 5-year average of 27.52%, near the high end of its 5-year range (24.72%–33.11%).
13.04% above its 12-month average of 29.29%.
Annual fiscal-year return on assets; no daily interpolation. Historical series through 2025-12-31.
RETURN ON ASSETS (ROA)
33.11%
RETURN ON ASSETS (ROA) AVG TTM
29.29%
RETURN ON ASSETS (ROA) AVG 3Y
27.30%
RETURN ON ASSETS (ROA) AVG 5Y
27.52%
RETURN ON ASSETS (ROA) AVG 10Y
23.26%
RETURN ON ASSETS (ROA) AVG 15Y
20.74%
RETURN ON ASSETS (ROA) AVG 20Y
19.44%
CURRENT VS TTM AVG
+13.04%
CURRENT VS 3Y AVG
+21.26%
CURRENT VS 5Y AVG
+20.31%
CURRENT VS 10Y AVG
+42.34%
CURRENT VS 15Y AVG
+59.63%
CURRENT VS 20Y AVG
+70.31%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+544.16%
vs the sector median at left
IDEXX Laboratories, Inc.
Market Cap
$40.64B
Return on Assets (ROA)
33.11%
TTM Avg
29.29%
3Y Avg
27.30%
5Y Avg
27.52%
Market Cap
$40.89B
Return on Assets (ROA)
10.31%
TTM Avg
10.56%
3Y Avg
11.14%
5Y Avg
10.55%
Market Cap
$42.30B
Return on Assets (ROA)
4.60%
TTM Avg
4.82%
3Y Avg
4.76%
5Y Avg
4.01%
Market Cap
$42.92B
Return on Assets (ROA)
1.77%
TTM Avg
-0.35%
3Y Avg
-1.89%
5Y Avg
-2.43%
Market Cap
$34.52B
Return on Assets (ROA)
14.54%
TTM Avg
-0.12%
3Y Avg
-10.91%
5Y Avg
-15.37%
Market Cap
$31.91B
Return on Assets (ROA)
16.99%
TTM Avg
17.06%
3Y Avg
15.57%
5Y Avg
14.60%
Market Cap
$49.54B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $40.64B | 33.11% | 29.29% | 27.30% | 27.52% |
| Agilent Technologies, Inc. (A)vs › | $40.89B | 10.31% | 10.56% | 11.14% | 10.55% |
| IQVIA Holdings Inc. (IQV)vs › | $42.30B | 4.60% | 4.82% | 4.76% | 4.01% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.92B | 1.77% | -0.35% | -1.89% | -2.43% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.52B | 14.54% | -0.12% | -10.91% | -15.37% |
| Alcon Inc. (ALC)vs › | $33.37B | 2.06% | 3.23% | 2.72% | 1.72% |
| Humana Inc. (HUM)vs › | $48.03B | 2.23% | 2.52% | 4.20% | 5.49% |
| ResMed Inc. (RMD)vs › | $31.91B | 16.99% | 17.06% | 15.57% | 14.60% |
| Becton, Dickinson and Company (BDX)vs › | $49.54B | 1.85% | 3.00% | 3.04% | 2.95% |
| Centene Corp. (CNC)vs › | $31.66B | -6.14% | -2.29% | 0.04% | 0.75% |
ROA
33.1%
ROE
70.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 31.62% |
| 2024-12-31 | 26.96% |
| 2023-12-31 | 25.92% |
| 2022-12-31 | 24.72% |
| 2021-12-31 | 30.56% |
| 2020-12-31 | 25.35% |
| 2019-12-31 | 23.34% |
| 2018-12-31 | 24.52% |
| 2017-12-31 | 15.36% |
| 2016-12-31 | 14.51% |
| 2015-12-31 | 13.02% |
| 2014-12-31 | 13.14% |
| 2013-12-31 | 15.26% |
| 2012-12-31 | 16.15% |
| 2011-12-31 | 15.69% |
| 2010-12-31 | 15.75% |
| 2009-12-31 | 15.12% |
| 2008-12-31 | 15.18% |
| 2007-12-31 | 13.39% |
| 2006-12-31 | 16.74% |
| 2005-12-31 | 15.95% |
| 2004-12-31 | 15.23% |
| 2003-12-31 | 10.94% |
| 2002-12-31 | 10.89% |
| 2001-12-31 | 10.08% |
| 2000-12-31 | 10.91% |
| 1999-12-31 | 9.05% |
| 1998-12-31 | -3.89% |
| 1997-12-31 | -5.60% |
| 1996-12-31 | 8.72% |
